Skip to content

LENSAR, Inc. LNSR Cash & Equivalents

Cash & Equivalents at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$21.69B-43.6%
Staar Surgical logo
Staar SurgicalSTAA
$131.86M-23.8%
Bausch + Lomb logo
Bausch + LombBLCO
$279M+29.8%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$36.52M+195%
Schering-Plough logo
Schering-PloughSGP
$238.9M+312%
IAR
Integra LifeSciencesIART
$236.81M-1.0%

Other financials

Income statement

See full
Revenue$13.4M-5.2%
Gross profit$6.4M-10.4%
Operating income$2.2M+139%
Net income$36.3M+233%
EPS (diluted)$0.00+100%

Balance sheet

See full
Total debt$7.6M+206%
Total equity$10.8M+149%
Total assets$66.2M-9.2%

Cash flow

See full
Operating cash flow-$4.3M+38.4%
CapEx$77.0K-31.9%
Free cash flow-

Valuation

See full
Market cap$70.13M-53.1%
Enterprise value$65.21M-54.9%
P/E2.4×
P/S1.2×-1.3×

Profitability

See full
Gross margin45.7%-2.1pp
Operating margin-28.7%+7.3pp
Net margin50.9%+30.7pp
FCF margin-26.6%

Returns & leverage

See full
Return on equity-164%-235pp
Debt / equity0.7×
Current ratio2.4×+0.6×

Where this comes from

Reported directly by LENSAR, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: LENSAR, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about LENSAR, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LENSAR, Inc.'s cash & equivalents?
LENSAR, Inc. (LNSR) reported cash & equivalents of $12.49M in Q1 2026.
How has LENSAR, Inc.'s cash & equivalents changed year-over-year?
LENSAR, Inc.'s cash & equivalents decreased by 36.1% year-over-year, from $19.55M to $12.49M.
What is the long-term trend for LENSAR, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), LENSAR, Inc.'s cash & equivalents has grown at a -20.4% compound annual growth rate (CAGR), from $40.6M to $12.97M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.